A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira® and US Sourced Humira®) in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Healthy
- Sponsor
- Samsung Bioepis Co., Ltd.
- Enrollment
- 189
- Locations
- 1
- Primary Endpoint
- Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to compare the pharmacokinetics, safety, tolerability, and immunogenicity of SB5 and Humira (EU sourced Humira® and US sourced Humira®) in healthy subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy subjects
- •Have a body mass index between 20.0 and 29.9 kg/m², inclusive.
Exclusion Criteria
- •History and/or current presence of clinical significant atopic allergy, hypersensitivity or allergic reactions, also including known or suspected clinically relevant drug hypersensitivity to any components of the test and reference investigational product formulation or comparable drugs
- •Active or latent Tuberculosis or who have a history of Tuberculosis
- •History of invasive systemic fungal infections or other opportunistic infections
- •Systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process
- •Serious infection associated with hospitalisation and/or which required intravenous antibiotics
- •History of and/or current cardiac disease
- •Have received live vaccine(s) within 4 weeks prior to Screening or who will require live vaccine(s) between Screening and the final study visit
- •Intake medication with a half-life \> 24 h within 4 weeks or 10 half-lives of the medication prior to investigational product administration
Outcomes
Primary Outcomes
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
Time Frame: 0 to 1680 hours post-dose
pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose
Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
Time Frame: 0 to 1680 hours post-dose
pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose
Maximum Serum Concentration (Cmax)
Time Frame: pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose
pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose
Secondary Outcomes
- Time to Cmax (Tmax)(pre-dose (0 h) and at 6, 12, 24, 48, 72, 96, 108, 120, 132, 144, 168, 336, 504, 672, 1008, 1344, and 1680 h post-dose)